Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy

European Journal of Immunology

Volumn 40, Issue 6, 2010, Pages 1786-1794

  Godet, Yann ^a   Desfrançois, Juliette ^a   Vignard, Virginie ^a,b   Schadendorf, Dirk ^c   Khammari, Amir ^a,b   Dreno, Brigitte ^a,b   Jotereau, Francine ^a   Labarrière, Nathalie ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Immunotherapy; Melanoma; MELOE 1; T cell repertoire; TCR

Indexed keywords

ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MELOE 1 ANTIGEN; MELOE 1 [36-44] PEPTIDE; MELOE A2 ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR; TETRAMER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL CLONE; CONTROLLED STUDY; DONOR; HUMAN; HUMAN CELL; MELANOMA; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; STAINING;

EID: 77953308650     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200940132     Document Type: Article

References (35)

1. Vujanovic, L. and Butterfield, L. H., Melanoma cancer vaccines and anti-tumor T cell responses. J. Cell Biochem. 2007. 102: 301-310.
2. Jager, E., Hohn, H., Necker, A., Forster, R., Karbach, J., Freitag, K., Neukirch, C. et al., Peptide-specific CD8+T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int. J. Cancer 2002. 98: 376-388.
3. Jager, E., Maeurer, M., Hohn, H., Karbach, J., Jager, D., Zidianakis, Z., Bakhshandeh-Bath, A. et al., Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int. J. Cancer 2000. 86: 538-547.
4. Benlalam, H., Vignard, V., Khammari, A., Bonnin, A., Godet, Y., Pandolfino, M. C., Jotereau, F. et al., Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol. Immunother. 2007. 56: 515-526.
5. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L. et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002. 298: 850-854.
6. Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J. and Andreesen, R., Phase I study of adoptive T-cell therapy using antigenspecific CD81T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 2006. 24: 5060-5069.
7. Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R. and Mackensen, A., Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 2003. 170: 2161-2169. (Pubitemid 36197440)
8. Vignard, V., Lemercier, B., Lim, A., Pandolfino, M. C., Guilloux, Y., Khammari, A., Rabu,C. et al., Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 2005. 175: 4797-4805. (Pubitemid 41362023)
9. Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E. and Greenberg, P. D., Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002. 99: 16168-16173.
10. Godet, Y., Moreau-Aubry, A., Guilloux, Y., Vignard, V., Khammari, A., Dreno, B., Jotereau, F. and Labarriere, N., MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J. Exp. Med. 2008. 205: 2673-2682.
11. Rizzuto, G. A., Merghoub, T., Hirschhorn-Cymerman, D., Liu, C., Lesokhin, A. M., Sahawneh, D., Zhong, H. et al., Self-antigen-specific CD81T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 2009. 206: 849-866.
12. Dunbar, P. R., Smith, C. L., Chao, D., Salio, M., Shepherd, D., Mirza, F., Lipp, M. et al., A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 2000. 165: 6644-6652.
13. Pittet, M. J., Zippelius, A., Valmori, D., Speiser, D. E., Cerottini, J. C. and Romero, P., Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 2002. 23: 325-328.
14. Zippelius, A., Pittet, M. J., Batard, P., Rufer, N., de Smedt, M., Guillaume, P., Ellefsen, K. et al., Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 2002. 195: 485-494.
15. Chaux, P., Vantomme, V., Coulie, P., Boon, T. and van der Bruggen, P., Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer 1998. 77: 538-542.
16. Dietrich, P. Y., LeGal, F.A., Dutoit,V., Pittet,M. J., Trautman, L., Zippelius, A., Cognet, I. et al., Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 2003. 170: 5103-5109. (Pubitemid 36554741)
17. Trautmann, L., Labarriere, N., Jotereau, F., Karanikas, V., Gervois, N., Connerotte, T., Coulie, P. and Bonneville,M., Dominant TCR Valpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur. J. Immunol. 2002. 32: 3181-3190.
18. Ding, Y. H., Smith, K. J., Garboczi, D. N., Utz, U., Biddison,W. E. and Wiley, D. C., Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 1998. 8: 403-411.
19. Garcia, K. C., Degano, M., Pease, L. R., Huang, M., Peterson, P. A., Teyton, L. and Wilson, I. A., Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998. 279: 1166-1172.
20. Moon, J. J., Chu, H. H., Pepper, M., McSorley, S. J., Jameson, S. C., Kedl, R. M. and Jenkins, M. K., Naïve CD4(+)T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007. 27: 203-213.
21. Klebanoff, C. A., Gattinoni, L., Restifo, N. P., CD8+T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006, 211, 214-224.
22. Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., Palmer, D. C. et al., Central memory self/tumorreactive CD8+T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 2005. 102: 9571-9576.
23. + memory T cell subsets in persistent EBV infection are differentiate d by migratory receptor expression Eur. J. Immunol. 2000. 30: 1823-1829.
24. Bodinier, M., Peyrat, M. A., Tournay, C., Davodeau, F., Romagne, F., Bonneville, M. and Lang, F., Efficient detection and immunomagnetic sorting of specific T cells usingmultimers of MHC class I and peptidewith reduced CD8 binding. Nat. Med. 2000. 6: 707-710.
25. Labarriere, N., Gervois, N., Bonnin, A., Bouquie, R., Jotereau, F. and Lang, F., PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol. Immunother. 2008. 57: 185-195.
26. Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Lienard, D., Lejeune, F., Fleischhauer, K. et al., High frequencies of naïve Melan-A/ MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 1999. 190: 705-715.
27. Lonchay, C., van der Bruggen, P., Connerotte, T., Hanagiri, T., Coulie, P., Colau, D., Lucas, S. et al., Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 2004. 101: 14631-14638.
28. Valmori, D., Dutoit, V., Lienard, D., Rimoldi, D., Pittet, M. J., Champagne, P., Ellefsen, K. et al., Naturally occurring human lymphocyte antigen-A2 restricted CD81T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000. 60: 4499-4506. (Pubitemid 32103631)
29. Voelter, V., Rufer, N., Reynard, S., Greub, G., Brookes, R., Guillaume, P., Grosjean, F. et al., Characterization of Melan-A reactive memory CD8+T cells in a healthy donor. Int. Immunol. 2008. 20: 1087-1096.
30. Correia-Neves, M.,Waltzinger, C., Mathis, D. and Benoist, C., The shaping of the T cell repertoire. Immunity 2001. 14: 21-32.
31. Sant'Angelo, D. B., Waterbury, P. G., Cohen, B. E., Martin, W. D., Van Kaer, L., Hayday, A. C. and Janeway, C. A., Jr., The imprint of intrathymic self-peptides on the mature T cell receptor repertoire. Immunity 1997. 7: 517-524.
32. Gervois, N., Labarriere, N., Le Guiner, S., Pandolfino, M. C., Fonteneau, J. F., Guilloux, Y., Diez, E. et al., High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clin. Cancer Res. 2000. 6: 1459-1467.
33. Jotereau, F., Pandolfino, M. C., Boudart, D., Diez, E., Dreno, B., Douillard, J. Y., Muller, J. Y. and LeMevel, B., High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J. Immunother. 1991. 10: 405-411.
34. Davodeau, F., Difilippantonio, M., Roldan, E., Malissen, M., Casanova, J. L., Couedel, C., Morcet, J. F. et al., The tight interallelic positional coincidence that distinguishes T-cell receptor Jalpha usage does not result from homologous chromosomal pairing during ValphaJalpha rearrangement. EMBO J. 2001. 20: 4717-4729.
35. Arden, B., Clark, S. P., Kabelitz, D. and Mak, T. W., Human T-cell receptor variable gene segment families. Immunogenetics 1995. 42: 455-500. (Pubitemid 26025063)